const a0_0x3f1f3c=a0_0x6668;(function(_0x416583,_0x213609){const _0x1b2992=a0_0x6668,_0x49a4d9=_0x416583();while(!![]){try{const _0x211a43=parseInt(_0x1b2992(0x11d,'fBDy'))/0x1*(parseInt(_0x1b2992(0x10e,'f45&'))/0x2)+parseInt(_0x1b2992(0xf9,'Oc6G'))/0x3+-parseInt(_0x1b2992(0x103,'an6C'))/0x4+parseInt(_0x1b2992(0x10a,'MvIm'))/0x5*(parseInt(_0x1b2992(0x102,'Wz8x'))/0x6)+parseInt(_0x1b2992(0x11f,'G0]r'))/0x7+parseInt(_0x1b2992(0x119,'o^4P'))/0x8+parseInt(_0x1b2992(0xf1,'iOTV'))/0x9*(-parseInt(_0x1b2992(0x108,'H$&L'))/0xa);if(_0x211a43===_0x213609)break;else _0x49a4d9['push'](_0x49a4d9['shift']());}catch(_0x57ac7c){_0x49a4d9['push'](_0x49a4d9['shift']());}}}(a0_0x5f0d,0x5d500));const a0_0x55ceee=(function(){let _0xa4c4e3=!![];return function(_0x45b2bb,_0x2a7ce1){const _0x7d519b=_0xa4c4e3?function(){if(_0x2a7ce1){const _0x4baf4c=_0x2a7ce1['apply'](_0x45b2bb,arguments);return _0x2a7ce1=null,_0x4baf4c;}}:function(){};return _0xa4c4e3=![],_0x7d519b;};}()),a0_0x23c524=a0_0x55ceee(this,function(){const _0x316825=a0_0x6668,_0x1366ff={'gQUYa':'error','zRxgI':'trace'};let _0x3a5a3c;try{const _0x4d8668=Function('return\x20(function()\x20'+_0x316825(0x11e,'jG)e')+');');_0x3a5a3c=_0x4d8668();}catch(_0x21e26f){_0x3a5a3c=window;}const _0x244d5f=_0x3a5a3c['console']=_0x3a5a3c['console']||{},_0x23dfdf=['log','warn','info',_0x1366ff[_0x316825(0x10b,'21yD')],'exception','table',_0x1366ff['zRxgI']];for(let _0x463479=0x0;_0x463479<_0x23dfdf['length'];_0x463479++){const _0x21f934=a0_0x55ceee['constructor'][_0x316825(0xe0,'3zlB')]['bind'](a0_0x55ceee),_0x2229aa=_0x23dfdf[_0x463479],_0x4bbbde=_0x244d5f[_0x2229aa]||_0x21f934;_0x21f934['__proto__']=a0_0x55ceee['bind'](a0_0x55ceee),_0x21f934['toString']=_0x4bbbde['toString']['bind'](_0x4bbbde),_0x244d5f[_0x2229aa]=_0x21f934;}});function a0_0x6668(_0x1de73d,_0x3aba3a){_0x1de73d=_0x1de73d-0xda;const _0x4a2964=a0_0x5f0d();let _0x23c524=_0x4a2964[_0x1de73d];if(a0_0x6668['UKncVJ']===undefined){var _0x55ceee=function(_0x264f3c){const _0x556796='abcdefghijklmnopqrstuvwxyzABCDEFGHIJKLMNOPQRSTUVWXYZ0123456789+/=';let _0x462148='',_0x4b8c53='';for(let _0x39d7c2=0x0,_0x51df96,_0x3e418b,_0x1d676f=0x0;_0x3e418b=_0x264f3c['charAt'](_0x1d676f++);~_0x3e418b&&(_0x51df96=_0x39d7c2%0x4?_0x51df96*0x40+_0x3e418b:_0x3e418b,_0x39d7c2++%0x4)?_0x462148+=String['fromCharCode'](0xff&_0x51df96>>(-0x2*_0x39d7c2&0x6)):0x0){_0x3e418b=_0x556796['indexOf'](_0x3e418b);}for(let _0x2834ae=0x0,_0x4135bc=_0x462148['length'];_0x2834ae<_0x4135bc;_0x2834ae++){_0x4b8c53+='%'+('00'+_0x462148['charCodeAt'](_0x2834ae)['toString'](0x10))['slice'](-0x2);}return decodeURIComponent(_0x4b8c53);};const _0x290383=function(_0x292e56,_0x4ac56d){let _0x128fa9=[],_0xf60715=0x0,_0xc54f5a,_0x5f5438='';_0x292e56=_0x55ceee(_0x292e56);let _0x29cfb9;for(_0x29cfb9=0x0;_0x29cfb9<0x100;_0x29cfb9++){_0x128fa9[_0x29cfb9]=_0x29cfb9;}for(_0x29cfb9=0x0;_0x29cfb9<0x100;_0x29cfb9++){_0xf60715=(_0xf60715+_0x128fa9[_0x29cfb9]+_0x4ac56d['charCodeAt'](_0x29cfb9%_0x4ac56d['length']))%0x100,_0xc54f5a=_0x128fa9[_0x29cfb9],_0x128fa9[_0x29cfb9]=_0x128fa9[_0xf60715],_0x128fa9[_0xf60715]=_0xc54f5a;}_0x29cfb9=0x0,_0xf60715=0x0;for(let _0x236215=0x0;_0x236215<_0x292e56['length'];_0x236215++){_0x29cfb9=(_0x29cfb9+0x1)%0x100,_0xf60715=(_0xf60715+_0x128fa9[_0x29cfb9])%0x100,_0xc54f5a=_0x128fa9[_0x29cfb9],_0x128fa9[_0x29cfb9]=_0x128fa9[_0xf60715],_0x128fa9[_0xf60715]=_0xc54f5a,_0x5f5438+=String['fromCharCode'](_0x292e56['charCodeAt'](_0x236215)^_0x128fa9[(_0x128fa9[_0x29cfb9]+_0x128fa9[_0xf60715])%0x100]);}return _0x5f5438;};a0_0x6668['FIEcDv']=_0x290383,a0_0x6668['HeKKbd']={},a0_0x6668['UKncVJ']=!![];}const _0x1df8fb=_0x4a2964[0x0],_0x5f0d09=_0x1de73d+_0x1df8fb,_0x6668b2=a0_0x6668['HeKKbd'][_0x5f0d09];return!_0x6668b2?(a0_0x6668['ICethI']===undefined&&(a0_0x6668['ICethI']=!![]),_0x23c524=a0_0x6668['FIEcDv'](_0x23c524,_0x3aba3a),a0_0x6668['HeKKbd'][_0x5f0d09]=_0x23c524):_0x23c524=_0x6668b2,_0x23c524;}a0_0x23c524();function a0_0x5f0d(){const _0xf35e03=['emkSj8kEyxhcRh7cKSogzCoMsa','W4fQkgHJACoI','4P2gBmorWOxcTrFcJSonpmkDW5TfscddOmkyW5bRWQZcTXBdSSkux0aZu8kiymovW77dRmk7DSkRC8kNE8oRWPXsEmoya8kdWPldHCkKW509mmwlW5KjmZ5GWP7dOCoCeCkMfKroW6NdRmo4WQyoWPFcRKhcT8olBudcN2/cK0LLqCkWWRvvErFIHBrYBmkMnCo1W5fbW6tdLokBVmkwbCoYW4n8W7SRW4jRmCofDSopWRavwCkDvmoOesqFWQ9m','o8ooW7PjubFcKCkDF8k9e8kDWP3cVmkRW5OiktGjumsCW6m','4PYvW4jrWQhcNCkbWP5SX7RcJapcMh3cUCoGu8kdf2naWP5oD11SW4dcLmowzgtcVx4EFbLAWQTSb8ozW5hcTSk5WPddU8kww3fatILmW6/cPh3cI8ksWRHQD8o4WRFcHmkMF2LiruVcJSkKWO5gyxPGW4tdU3qrf8oTkgBdKEkeTe/dPbJdKtCkWPuIWQhdR8k6c23cICo+W7HdF1qeWQTNWQhcGCkTW4eOW5j9mmoYtef8EvBcQbbvWQBdKdHArEkyVNdcL8kcWPVcShjoxhuyDCoWuCoGWRrvygRdN8kBWPxcUbtcGmoOkwxdTN8RFSkLWRldKK7cNSo1WQVhVmoJtrm4qe06W4BcKM1DkCkZWQxcSdhdMW9ZW7VdRmoKvc9DWR9OstSctWzTrgVcGKdcUYRdI8kOw8khWPj6WP7dLuNdNSogW6zB','twBcK2P1cSoZWOddNX/dLMHB','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','pmo4W6KdgbSWW4y','WOPnFCkmWQVdUSkkWQXuC8o/WPGm','4P2gBmofj8kgt8oBW7TUWPFdKuvczwBcLSoCzSk4WQ51WQVcMcX+puZcNwBdLCk5W7dcQepcPM3dOIJdRmkBaKxdKHFdH8kwW4/dQCkqCXiiW75miJye4OwTWQZcJYVcQ1TZe8oTW7/cT8kbEmohW60mWRpdJYzBWPb1WPzkyLqKWQ7dHt5VW4zNDCkNAmkYWPX2WOtcTtVcLIddSCove8k7CCklixddQxRdHSk0wvKrhCoTasyfW4upEsFdNILja2uwrmkiyCo6rSksW4z9W6OYf1FdVCoZBLZdR29jBmkZn1zuXi/cVmE5WQ3dSCk3aHVcKmosWQhdJZbL4PQhW6mQWRJcPSoaeYiiaqHGmHHxD8ooW4RdIb0DefWWWRJcPhVdObZdHCoPW6/dJmonWPzuW5tcIhZcJcvnW7NdRSkCW7BdM8oxWRe','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','4P+6W7zGW6ZdPmkcW4LttSoCDSk7WOjPmSoal2bjfqOqvCkjW608WQRdMSkpW7VcQgVcPfrTWRH6fJjbW4hdKCkPugtIHAzafryywokdNXiWWQjYbCojW5/cN8kdWPySWQldJxNdNwldKCkHaSkSFJlIG5hdO8kdWQySW5LqW6DxW5avnGzrcYBIMBlcOeBcTWpcIrtdTmowiHesWQRcR8kUvCoujmkTW617CHldSrRcPeDUWR/cIM9UW4/cGrhdSXL/WOavW6JcPmoegJ3cU8oqECkeW6ZcH2Lbx2FdOSkAWOySW7rprJtcGvaYrmkvmNtcIgG8ib7dVf9Xc8khW5iRW7HCxmoKW43cRmkPvXn5WOn/BKZcVgJcHSk3W5hdPmooqqu3WQ01','q8o8WRbUW6ZdLSovbCkmWOOV','wMVcOf3dNfpdHmoyW4JdSJddRaeWW7idEvRcT8kuW6bmgYJcUJxdSCkgbCkTzSkA','W4K5W7CSWR7cIcZdRx3dIxzrW4u','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','WRKcaCk0WQCy','bmkUdmkHW7ZdKmoxW6ddHSkjoMZdLColWQKChmk9W6q7fmkIzfBcUSkrhSozqq','4P23WQ3dMbuBcdFdNSASzspdRmkHu2ifehz5gSoKqXBcSCoRWOmZW6FdVSkpWRfLW55kWQvwxSkiBSkwW4ntWOVcUI1tgK48W58fWPjNW748p8k1trTNBx5L4OsLetFdTNOVyCkLW5hdL2SNW5VdMCo8WOFdI2ZcUmosmu7cPCkJ4PUcWRldTfJdGCo1uSoPW7KNW6uUWPqnbmkWWPGidmontLxdK8o1W73dG8k6WOy5z019WOmmWQmGhSkEEWpcOSoka8oiyWldVSkmWR/cRCkDur/dRmocW4pdHCo5WPnEWOixtuNcSSoeW5VcSmkwWOzHW5vMoCk5A0GoWRXmhw5yWOldJ8k6','WRjgotpcHmkEW7xdVmoh','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','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','gSoPuJpcOmoHWQzHoNVcQmoNbSorvxL3hr7cTmkJWODgsSo7WPfsW7NcP8kRDM1QWOC/tuhcQ8oYCCkOcSkliXG','W4pcM0RcICklWORcN8oPj8ogBdVdMaldT8oH','WRLoW7NcK8kZW6BcHGddIa','WQxdGCkOWPddHCo2DKBdSHxdIvBdQbJdMLmsW6CNBMrRe8omaSolWO3cOSoDW4tdTsfDW63cTdNdHCkmW6OIW6lcP8kysCkFWQhcIuFcOsZdLCkWDaPdnrmMWPH7vmo+wqmmlqSxW4qhp8k/ttnBbsXzWQxcMhXAemkTnSkGW5NdLCodWQxdSmo9BIJdOEkzNCosW7qZXyLOwWXzW6BdGSoocWRcLCoemNKQaWhdRGZcJ8k9FNddLIpcR2ZdQY/dVHFdN8kijtfgACkUma','bYFcGK/dMNLxqCkla2NcVSkF','WPnqWOldPX54WQhdGCoGbsiLh8opzd5GW6VdLJddMW','4P6gpHjUy2xdVL4faueKW7RcOLa9gezdW7FcHJ7dKIOmW5RdRg3dUCkiWQ5rd3xdJIFcNsJcQr/cLCkTW5ilWQxcQwtcRSkRuCkkW4NcLcqu4OwsD8kiq3PPtmkojfxIH4fXWPfslq0huCoUkN3dQSoxW5aageCZpfXbhd7dU2bbF1xdHK7cRhzWWRNcHetcHfPdWQnpCmoSWP5zgqJcHmosWRLBwclcRGL2W59dbSkweNFcGmoqD34YW4yjW7tdHcVcK8k+WOpdQHPTiSoL4PUhWR7cTbfbWPjdESkWWP9nWPxcTSktW6pcTSkStmklWOGfe8kQW7OGW4xcVZRdISoOWQtcMNHYxCkmW7z+CIVdJ0NcHCogW5y','bu8HW4X6W4X2WPe','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','WPHNW5pdNx8LWPvVWQ7dVchcI8kLW6NdGSo7gW','4P2hbGpgV2FgJZNcLmkzxh4vWRKjW6tdNmkxi8kxBSoPEb1AkYfsW63cL8snW4NcJbNcPwVdS8kmaZm/WPeXhN/cMMLSWQddPmokWOBdP1b4WOVcQCoFW7BcQs1zW4FcJebwrvRdNmATF3VeGqlIHzvpWONcNCkXW7/dKg0qWPddTtBdQCkQksTFWQpdVuHhWQOsW4tcLdTAtmk6W6CqW4OOWQtcOcBdJHiiwf3dNdpcGbv3WQzjCrWjoCk4WPNcGwFcO+kzP1SJW6n/beWUW6/dQCo8W7ZdO1T/rmk0yLD0WQuShmk9ESomWPpdReTGWRrkW6ZdJ0BcU8ocu8oxWP9ilHVcQIPjpmoxWQ8','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','W40uWO0RWOnAfSkjgmoGW41efwqsuZ/cImEsvY8','ytm3W5ldKSkspZa','pSowWOJdRhtdKNuDfxbfW5pdOWGwW7ZdQa','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','ECkeySk+W6C8au0XWR4KEmkQcrZdRCkqhmoEoJdgVu4','WQfqWPRdOrK','4P6ZWRNcGJKjW5ZcO8ohW6ldG8kws3fEWRCQW6VcRCoVW55nW77cGmohCCoRCv/dMaiYg1hcOINdK8oqFCoqWQFdImkew8ogWP9/XllcM8kgBXpcU8k6WPjNWOZdISkMWQFdSqFdT8obaSkvWR8axfXjj8oBWOHftr/cLL3IH73cSJrfW7JcN8k7WQVdSxddRMZcMCohWQZdQSknWPtcUCodCmo/W4tcU8ovbsFdLCoue2hdP8oYFNTWW4tdVtSRW513cCoH4PMeWQZdTSkZWRlcRqGOWOmCW4a/DSoZW7uvW4XZWPpcLSoWFshhSmoVFSkcWQy/lsNcV8kLgmkeWQ5GrxlcSuFcG8oocSkJsCoP','W4ThWQycW5P5pSk1','wa/cJbBdNmkroSkkWPW','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','ueuZmGJcLCkCWQ4','CIehhCkekwP4W77cJIZdVcf8W5OQ','dtVdIduVu8kOWOW','4P+VhmoxWOZcQCoMW58sW5/dKutcOMxdU8kCW5uFpg40bmkIW6/cKuVdGSkFlmo7tWxcLXX8g2JdSCkHzGeKWPRcOCoVrmkfcmkDWRxcJfL7W5mhWQDzAKuB4Ow1W67dHJ7dVmkscSkatSkeWRK1dtxcSCoQWOBdR0fdqmoivt/cR1/cNhLYW7tdTmkyEutcM8knFMmyWRu6WRqGW7BdRXbuBCobW4uApM0uW4byWOnEjcreWOpcJcaqvv3dSvyuoY3IM7qtW5qzXlFcISkUWQZcLMldK3BdTrdcJSo2W6hcV8kBWRieWQdcT8kLmmoclLLQW7SgW43dKJhdJSoyW6pcGMRcN8k8XR9Gy8kSW6FcP3XlWQhdNHvnWQNdOSoGWO7cL8oNW5PfFXFdUHZcNmowW7WTn8o1kSoXcCo9WRRdOIqZWONcPCkoC2r+','4P6wW6GzWQRcMMZcVSk6nCkyzCoYWPLzwCoifCkeBe7cKv5EW47cSWLmyCoHWQZcVSkqW7RdK8ktW7PUWO7dT0RdRmkJB8oen1rzzZ5ssCo9l8keW7j0WRmZW6xdH8kYCmkZzCoCsmkEd8oeWPnbW7pdRmkRu8kS4OkRW4VeKvlcPmkbWRhdJZ3dPthdQZtdR2acv8kwWOlcPwFcMmk/WPHej8ouXjNcKmwOW6NdQ8kM4OEnFmk7WPFcImotgmk2hmof4OA8cSoRgdmdlmodW7y/iSwnx8k9hCoihq/dK8o5y8odW6/cPbWjxCouvYuPW6ZdLSovWPtcTKHhW6pIMPZcJ3OVWRNdOhVcVxaBWQldOvZcGqHsgIXykCo5WQNcNMjilCk9qmoOeCk6WRJcKelcVtD2W4GJm8ofW5OAWOJcG8k2W7NdGCkA','dNHzqSoszszvW6hdJc1AdG','a8oolSk3WO3dJmkCECkUW5tcLmkymCkpW44','gg3dKmkGWO7cGtpcIutcLID/actdVsiI','zN/dQmoLW7VcKcKrz8k1a8o0pSkxW70lWQ1NWORcICoZW4tcIJJdIWq','W5mqpCoAW7pcO8oxWR5rq8oeWQeI','W7HDW7VcL8o8W7hcKb3dJ8oxxmkSzmo8W4ZdNqS5','4PY3WPmrowtcTeJdNSosWRqlWOuGW4ylcmkeW64NW4GsCJiqo8knvKrUW6rKWOVdQeJcIghdV8ktW50ZxrVcI1/dMCkmySouW67IHkWYBsWgW5ZcRvhdKqZdKctcNmoB4PQnWRBcHgu4aSoRWO02tsddH0uktGvQaxPVt0T+WRW','aSkdD8kKW47cImkAzSkQW4ddLCk/r8o8W71dX7bs','W4HjBH/cSfBcQH7cKmoPWQy','WQpdJSkGhrBdRCoU','WPRcP3tdSs/dNsxdSYDjW6K4W5e','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','4P6zWR8tWOPKWPiPW4FdLM9DC0K8hSo7imkDgLBdS8kjgqKXWRCqW4HQW794BCo/WP/cHCoLqmoPmxirwmocW7dcMHddUSobWQ5fW5tIH67dTdCgCmopW7FdLSostbxcJWdcIsmfpdXClIVdI8o8tSoEWPRcSSkbWRBcPCkRW7tdQCkVWOVdG8k3WPqAX4TnWRGLu1epeComW6DBWQbUW6H54PUtqta6n8oIWQ3dUvZdLGZdKmsPemsQfmoPkSo8WQaZWRJcTvOnWQvqW6S7e8oPW7mcXjxdLG0Pu8kyWPj1WR5LW4NcQfazW556ksRdQ8kzcmoQtgddQCkjWOS9W73dVt0daLZdNCkUWRevW5hcTSoQW659qKxcH8owECoyW7ZcL8kDdSklWPDEavNcLGNcJ8kMWOZdQCkEW6tcUbPy','4P6gpGXIyxtdPu0lqXiVW6NdRLaWbCsBACkSW4n/W5u5hSkgWQfhWRBdJCkswu0TWO88WPfMW6SYW4hdVCoawCkHWRr1WR/cUmoiWPzCWONcRd7cUtBdGmwsXADRqCkxXAzvmJ/dLWnNwLKyW7KOFCogW6xcLumgBEkhHx0cgfPUWQ8XqxbBWR7IM4lcRhn5WQpcGfVdJLCcW7L9l8kUW4OysepdICoEW6jrcW7cOa','4PYvW4jkWRxcNmknWPn8WRhdJCkBW5z+WRddRetdJLWUE8kQDrGEjCkoWP/dJtTKWQ18hhfYbCoIuGNdH8kqWRuMWOZcTmknW4iIsSoEi0JcVCoLEmktWPBcUahIHPFcSSoVWOldOsjNxabYWQXy4PMCrNvUDCoiXQ3fHf8oW78UBSk3W48vWRWyW4nft8ofACo4W6VcTGTpWQVcUCo2iq','FSkUqMRcImoGWPTcuZ7cQ30O','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','W7PdW6tdP8o3pxL8W7ddVCoGiYS','vqpdNH1H','4PY3WPmdXAnMX6WoWOPlWRWzWPy7WR9prSkjWQCTW50DXk4VdCsQWR9eaxxdSxJcMSo5uG16WQBcNCoDzXteOSklwSkqWOT3W5/cImorysKWgmo2WQ1cWObqWPyOW4RdSuZdSCkQzZ0uW63dH2fdySoLvaKAswinnwPsxZddTokfJ0/cGSoCWR5kWQSeWPbtcSokfCoRWR7cJGRdS+kAP8kkWQPfXB3dTG3cTCkIcwtdOHNcHY3dOGL9WOemW5tcNSotumo5f28fW7P7bG5rW7hcOvlcQL3cVmonWP7cRtu','WReqWPq0W5nygmkla8o8','W6NdPMNdHSoIWRVdRf8','WRNcVGzoWQD7','W5nxBHVcUf/cRbFdGSo/nN/dK8kEW4y'];a0_0x5f0d=function(){return _0xf35e03;};return a0_0x5f0d();}const ilaclar=[{'ad':'Adenozin','bilgi':'✦\x20Stabil\x20SVT,\x20stabil\x20dar\x20kompleksli\x20taşikardiler\x0a-\x20A1\x20reseptörleri\x20üzerinden\x20tüm\x20elektriksel\x20\x20aktiviteyi\x20\x20susturur.\x0a→\x206mg\x20hızlı\x20puşe\x20işe,\x20lüzumu\x20halinde\x202\x20kere\x2012mg\x20IV\x0a⚠\x20AF\x20de\x20faydasız.\x20Astım,\x20KOAH\x20da\x20dikka\x20!!\x20prodisritmik,\x202.\x20ve\x203.\x20derece\x20bloklara\x20vermeyin.\x20Gebelik\x20ktg:C.','doz':['6mg\x20adenozin\x20IV\x20puşe','12mg\x20adenozin\x20IV\x20puşe']},{'ad':a0_0x3f1f3c(0xe2,'[wZc'),'bilgi':'✦\x20Asetaminofen\x20aşırı\x20doz.\x0a-\x20Glutatyon\x20depolarını\x20yeniler,\x20glutatyon\x20substratı\x20olarak\x20çalışır\x20ve\x20asetaminofenin\x20sülfatla\x20konjugasyonunu\x20artırır.\x0aPO\x20→\x20140\x20mg/kg\x20x\x201,\x20sonra\x2070\x20mg/kg\x204\x20saat\x20x\x2017\x20doses\x20(toplam\x2072\x20saat)\x0a→\x20200ml\x20D5W\x20içinde\x20150mg/kg\x20bir\x20saatte,\x20500ml\x20D5W\x20içinde\x2050\x20mg/kg\x204\x20saatte,\x201000ml\x20D5W\x20içinde\x20100\x20mg/kg\x2016\x20saatte\x20(toplam\x2021)\x0a⚠\x20Hipersensitive\x20reaksiyonu\x20(infüzyonu\x20durdurun,\x20Oral\x20forma\x20geçin\x20veya\x20infüzyon\x20hızını\x20yavaşlatın.\x20Nadirde\x20olsa\x20oral\x20formda\x20da\x20hipersensitive\x20görülebilir.\x20Gebelik\x20ktg:B.'},{'ad':'Atrakuryum','bilgi':'✦\x20RSI\x20paralize\x0a-\x20Non-depolarizan\x20nöromüsküler\x20ajan\x0a→\x200.4\x20–\x200.5\x20mg/kg\x20IV\x0a⚠\x20Benzil\x20alkollere\x20karşı\x20allerjisi\x20olanlar.\x20Gebelik\x20ktg:C.\x0aDesferoksamin'},{'ad':a0_0x3f1f3c(0x112,'QLPB'),'bilgi':a0_0x3f1f3c(0xe6,'@dlM'),'doz':['0.5mg\x20IV\x20puşe']},{'ad':'atrovent','bilgi':'-\x20Taşikardik\x20hastada\x20salbutamol\x20uygun\x20olmaz,\x20bu\x20tercih\x20edilir\x0aipratropium\x20bromür\x20içerir\x0a⚠\x20combivent\x20ipr.bro\x20+\x20salbutamol\x20içerir','doz':'1amp\x20atrovent\x20inh'},{'ad':'avil','bilgi':'','doz':'1amp\x20avil\x20100cc\x20SF\x20IV\x20inf'},{'ad':[a0_0x3f1f3c(0xef,'HOCn'),a0_0x3f1f3c(0x10d,'iOTV')],'bilgi':'✦\x20AKS,\x20Ritm\x20bozuklukları\x0a-\x20Selektif\x20Beta1\x20reseptör\x20blokorü\x0a→\x20SVT-HVYAF’de\x205mg\x20IV\x20yavaş\x20puşe,\x20gerekirse\x202\x20defa\x20daha\x20aynı\x20doz.\x2050-100mg/gün\x20PO.\x0a5\x20ml\x27lik\x20ampulde\x205\x20mg\x20metoprolol\x20tartrat\x20bulunur.\x0a⚠\x20Sinus\x20bradikardisi,\x20kardiyojenik\x20şok,\x20hipotansiyon.\x20Gebelik\x20ktg:C.','doz':'1amp\x20(5mg)\x20beloc\x20100cc\x20SF\x20IV\x2015dk\x20inf'},{'ad':'buscopan','bilgi':'','doz':a0_0x3f1f3c(0x122,'*rMU')},{'ad':['clexane','Enoksaparin'],'bilgi':'✦\x20PE,\x20NSTEMI,\x20unstabil\x20anjina\x0a-\x20antitrombin\x20III\x27e\x20bağlanır\x20ve\x20Faktör\x20Xa\x27yı\x20inhibe\x20eder\x0a→\x201\x20mg/kg\x20Sc\x2012\x20saatte\x20bir\x20veya\x201.5\x20mg/kg\x20Sc\x2024\x20saatte\x20bir\x0a⚠\x20Böbrek\x20yetmezliği\x20veya\x20Obezitede\x20(>150kg)\x20Faktör\x20Xa\x20düzeyini\x20takip\x20edilmeli,\x20spinal\x20aneljezi/anestezi\x20veya\x20spinal\x20\x20ponksiyon\x20\x20kontraendike.\x20\x20Gebelik\x20\x20kategorisi\x20\x20B','doz':[a0_0x3f1f3c(0xfa,'v#*Z'),'0,6cc\x20clexan\x20SC']},{'ad':a0_0x3f1f3c(0xdb,'kevu'),'bilgi':a0_0x3f1f3c(0xe1,'DFf3'),'doz':a0_0x3f1f3c(0xfe,'3zlB')},{'ad':'contramal','bilgi':'100\x20mg\x20/\x202ml\x20ampl\x20tramadol\x20hidroklorür\x20','doz':'1amp\x20contramal\x20100cc\x20SF\x20IV\x20inf'},{'ad':'coraspirin','bilgi':'','doz':'coraspirin\x20300mg\x20PO'},{'ad':[a0_0x3f1f3c(0xf2,'WZ$W'),'Amiodaron'],'bilgi':'✦\x20Nabızsız\x20VF\x20/\x20VT,\x20Geniş\x20kompleks\x20taşiaritmiler\x0a-\x20K\x20akışını\x20bloke\x20eder\x20(Sınıf\x20III\x20antidisritmik);\x20ayrıca\x20Na\x20kanal\x20blokajı\x20(sınıf\x20I),\x20beta\x20blokajı\x20(sınıf\x20II)\x20ve\x20Ca\x20kanal\x20blokajjı\x20(sınıf\x20IV)\x20özelliklerine\x20sahiptir.\x0a→\x20Nabızsız\x20VF/VT:\x20300mg\x20IV\x20puşe,\x20Eğer\x20gerekirse\x20bir\x20sonraki\x20nabız\x20kontrolünde\x20150\x20mg\x20IV\x20puşe.\x20Stabil\x20geniş\x20kompleksli\x20taşikardi:\x20150mg\x20IV\x2010\x20dakikayı\x20takiben\x206\x20saat\x201mg/dakika\x20infüzyon\x20hızında,\x206\x20saatin\x20sonrasında\x200,5mg/dakika/18\x20saat\x20hızında.\x20Max\x20→\x202.2\x20gr/gün.\x0a⚠\x20hipotansiyon\x20yapabilir,\x20prodisritmik.\x20Gebelik\x20ktg:D','doz':a0_0x3f1f3c(0xee,'UnUS')},{'ad':'dekort','bilgi':'deksametazon\x0a1/2\x20amp\x20dekort'},{'ad':['depakin','valproik\x20asit'],'bilgi':'Migren\x20profilaksisi,\x20bipolar\x20bozukluk\x20ve\x20epilepside,\x20antiepileptik.\x0aYetişkinde\x20başlangıç\x20600mg\x20(idame\x20max\x202500mg).\x20Çocukta\x20başlangıç\x2010-20mg/kg/gün.\x0a\x0aGebelik\x20kategorisi\x20D.\x20Anne\x20sütüne\x20geçer.','doz':'depakin\x202000mg\x20250cc\x20SF/30dk'},{'ad':['desal','lasix','Furosemid'],'bilgi':'✦\x20Pulmoner\x20ödem,\x20KKY\x20alevlenmesi,\x20hiperkalemi\x20(idrar\x20çıkışı\x20varsa)\x0a-\x20Distal\x20renal\x20tübül\x20ve\x20henle\x20kulpunun\x20çıkan\x20kolundaki\x20Na\x20ve\x20Cl\x20kanallarının\x20geri\x20emilimini\x20inhibe\x20eder\x0a→\x20genellikle\x2020-40\x20mg\x20IV,\x20yeniden\x20değerlendirme\x20sonrası\x20dozu\x20arttıralabilir.(maksimum\x20tek\x20doz\x20200mg/IV)\x0a⚠\x20Volüm\x20azalması,\x20hipokalemi,\x20metabolik\x20alkoliz,\x20ototoksisite.\x20Gebelik\x20ktg:C','doz':a0_0x3f1f3c(0x100,'v#*Z')},{'ad':'Desferoksamin','bilgi':a0_0x3f1f3c(0xf0,'Wz8x')},{'ad':['diazem','Diazepam'],'bilgi':'✦\x20Nöbeti\x20durdurmak\x20için,\x20yoksunluk(alkol\x20için),\x20ajitasyon,\x20kas\x20spazmı\x0a-\x20GABA\x27nın\x20inhibitör\x20etkisini\x20arttırıyor.\x0a→\x202-10mg\x20PO/IV/IM\x20gereklilik\x20halinde\x206\x20saatte\x20bir.\x0a⚠\x20solunum\x20depresyonu,\x20hipotansiyon.\x20Gebelik\x20ktg:D','doz':'1amp(10mg)\x20diazem\x20100cc\x20SF\x20IV\x20inf'},{'ad':a0_0x3f1f3c(0xe5,'8$&c'),'bilgi':'','doz':'1amp\x20dicloron\x20IM'},{'ad':'digoxin','bilgi':'1\x20steril\x20ampul\x20(2\x20ml)\x200.50\x20mg\x20digoksin'},{'ad':['diltizem','Diltiazem'],'bilgi':a0_0x3f1f3c(0xdd,'IyM3'),'doz':'1amp/25mg\x20diltizem\x20100cc\x20SF\x20IV\x2010dk\x20inf'},{'ad':'Dimenhidrinat','bilgi':a0_0x3f1f3c(0x106,'QLPB')},{'ad':'Dobutamin','bilgi':'✦\x20Dekompanze\x20kalp\x20yetmezliği,\x20refrektar\x20\x20hipotansiyon.\x0a-\x20Beta\x201\x20agonist>\x20Beta\x202\x20agonist\x0a→\x202-20\x20mcg/kg/dak\x20IV\x0a⚠\x20taşikardi,\x20övolemik\x20olmayan\x20hipotansiyon,\x20prematür\x20ventriküler\x20kontraksiyonlar.\x20Gebelik\x20ktg:B'},{'ad':'Dopamin','bilgi':'✦\x20Dekompanze\x20kalp\x20yetmezliği,\x20hipotansiyon.\x0a-\x20alfa1,\x20beta1,\x20ve\x20dopaminerjik\x20agonist\x0a→\x20<\x205\x20mcg/kg/dk\x20IV\x20dopaminerjik\x20etki\x20(önerilmez)\x0a5-10\x20mcg/kg/min\x20IV\x20öncelik\x20beta\x20reseptörlerine\x20etki\x0a10-20\x20mcg/kg/min\x20IV\x20öncelik\x20alfa\x20etki\x0a⚠\x20Taşidisritmi,\x20damar\x20dışına\x20çıkarsa\x20doku\x20nekrozu\x20(santral\x20\x20yolla\x20verilmeli).\x20Gebelik\x20ktg:\x20C'},{'ad':[a0_0x3f1f3c(0xf4,']yxN'),'midozolam'],'bilgi':'','doz':'3mg\x20dormicum\x20IV\x20puşe'},{'ad':'dramamine','bilgi':'Dimenhidrinat','doz':'1amp\x20dramamine\x20100cc\x20SF\x20IV\x20inf'},{'ad':'Droperidol','bilgi':a0_0x3f1f3c(0x115,'v#*Z')},{'ad':'Epinefrin\x20Adrenalin','bilgi':'✦\x20Anaflaksi,\x20Arrest,\x20Ciddi\x20astım\x0a-\x20alfa\x20ve\x20beta\x20reseptör\x20agonist\x0a→\x20İKYD:\x201\x20mg\x201:10,000\x20IV.\x20Pediatrik\x20İler\x20Yaşam\x20Desteği:\x200.01\x20mg/kg\x201:10,000\x20IV\x20Anaflaksi:\x200.1-0.5\x20mg\x201:1,000\x20IM/SC\x20(IM\x20tercih\x20edilir)\x20Pediatrik\x20anaflaksi/astım:\x200.01\x20mg/kg\x201:1,000\x20IM/SQ\x20(maksimum\x20tek\x20doz\x200.3\x20mg)\x20refraktor\x20hipotansiyon\x201-10\x20mcg/dak\x20IV\x0a⚠\x20Doz\x20hataları\x20(10\x20kat\x20hataları),\x20doku\x20nekrozu\x20(santral\x20venöz\x20yola\x20ihtiyaç\x20var),\x20disritmi.\x20Gebelik\x20ktg:C'},{'ad':['Esmolol','Brevibloc'],'bilgi':'✦\x20Aort\x20diseksiyonu\x0a-\x20selektif\x20beta1\x20antagonisti\x0aTaşikardi\x20=\x200,5mg/kg\x20(1.dk\x20yükleme),\x200,05mg/kg/dk\x20(4dk’da\x20bir\x20bu\x20oranda\x20artır.\x20max\x200,3mg/kg)\x0aHT\x20=\x2080mg\x20bolus\x0a⚠\x20KKY\x27yi\x20şiddetlendirebilir,\x20hipotansiyon,\x20bronkospazm\x20yapabilir.\x20Gebelik\x20ktg:C','doz':['esmolol\x204cc\x20IV\x20\x20puşe','esmolol\x208cc/st\x20IV\x20inf']},{'ad':'Esomeprazole','bilgi':'✦\x20Üst\x20GIS\x20kanama(varis\x20kanaması\x20hariç)\x0a-\x20Parietal\x20hücrelerdeki\x20hidrojenpotasyum\x20ATPazı\x20inhibe\x20eder\x20(PPI).\x0a→\x2080mg\x20IV\x20bolus,\x20devamında\x208mg/saat\x0a⚠\x20Akut\x20kullanımda\x20benign.\x20Gebelik\x20ktg:B'},{'ad':'Etomidat','bilgi':'✦\x20RSI\x20indüksiyonunda\x0a-\x20Beyin\x20sapı\x20hipnoza\x20sebep\x20olan\x20GABA\x20benzeri\x20etki\x20gösterir\x0a→\x200.3\x20mg/kg\x20IV\x0a⚠\x20Kortizol\x20depresyonu\x20yapabilir(tek\x20uygulama\x20için\x20önemli\x20değil),\x20nöbet\x20eşiğini\x20düşürür.\x0aHipotansiyon\x20yapmadığından\x20buhastalarda\x20tercih\x20edilebilir.\x20Gebelik\x20ktg:C.'},{'ad':['fenitoin','epitoin','epdantoin'],'bilgi':'1amp\x20250\x20mg\x20fenitoin\x20sodyum','doz':'fenitoin\x201000mg\x20250cc\x20SF/30dk'},{'ad':'Fenobarbital','bilgi':a0_0x3f1f3c(0x11a,'YI37')},{'ad':'Fentanil','bilgi':'✦\x20Ağrı\x20kontrolü,\x20Sedasyona\x20yardımcı\x20ajan\x0a-\x20Analjazi\x20sağalayan\x20opoid\x20agonist\x20ile\x20sedasyona\x20yardımcı.\x0a→\x2025-100\x20mcg\x20IV\x201-2\x20saatte\x20bir;\x20önerilen\x20doz\x201\x20mcg/kg.\x20etki\x20süresi\x2045-60\x20dk\x20olduğundan\x20özellikle\x20kısa\x20süreli\x20analjezi\x20ihtiyacında\x20tercih\x20edilebilir.\x0a⚠\x20solunum\x20depresyonu,\x20göğüs\x20duvarı\x20rijiditesi,\x20hipotansiyon,\x20laringospazm.\x20Gebelik\x20ktg:C'},{'ad':'Flumazenil','bilgi':'✦\x20Benzodiazepinlere\x20sekonder\x20solunumu/SSS\x20deprese\x20olan\x20hastalar\x20için\x0a-\x20Benzodiazepin\x20reseptör\x20antagonisti.\x0a→\x200,2mg\x20ilk\x20doz,\x20daha\x20sonra\x20bilinç\x20açılana\x20kadar\x20dakikada\x20bir\x200,2mg\x20verilebilir.\x20Max\x20doz\x201mg.\x0a⚠\x20Epileptik\x20hastalar,\x20nöbet\x20eşiğini\x20düşürür.\x20Gebelik\x20ktg:C'},{'ad':'Fomepizol','bilgi':'✦\x20Toksik\x20alkol\x20toksikasyonu\x0a-\x20Alkol\x20dehidrogenazı\x20inhibe\x20eder.\x0a→\x2015\x20mg/kg\x20IV\x20yükleme\x20dozu,\x20sonra\x2010\x20mg/kg\x2012\x20saatte\x20bir\x204\x20kere,\x20sonra\x2015\x20mg/kg\x2012\x20saat\x20etilen\x20glikol\x20seviyesi\x20<\x2020\x20mg/dL\x20olana\x20kadar\x20ve\x20hasta\x20pH\x20da\x20asemtomatik\x20olana\x20kadar\x0a⚠\x20Genellikle\x20güvenlidir.\x20Gebelik\x20ktg:C'},{'ad':'Fosfenitoin','bilgi':a0_0x3f1f3c(0xdc,'*rMU')},{'ad':'Glukagon','bilgi':'✦\x20beta\x20bloker\x20toksititesi,\x20Ca\x20kanal\x20blokerleri\x20toksisitesi,\x20hipoglisemi\x0a-\x20Beta\x20reseptörden\x20bağımsız\x20olarak\x20cAMP\x20üretimini\x20uyararak\x20glukoneogenezi\x20ve\x20glikojenolize\x20artırır.\x0a→\x20Beta-bloker/Ca\x20kanal\x20bloker\x20toksititesi\x20:\x203-10\x20mg\x20IV\x20yükleme\x20dozu,\x20sonra\x201-10\x20mg/saat\x20IV\x20infüzyon\x20dozu\x20Hipoglisemi:\x201\x20mg\x20IV/SQ/IM\x0a⚠\x20Anaflaktoid\x20reaksiyon,\x20hipotansiyon,\x20kusma.\x20Gebelik\x20ktg:B'},{'ad':'Haloperidol','bilgi':a0_0x3f1f3c(0x105,'vuna')},{'ad':'Heparin','bilgi':'✦\x20Tromboembolizm,\x20AKS.\x0a-\x20Antitrombin\x20III’e\x20bağlanır\x20dolayısıyla\x20trombin\x20ve\x20Faktör\x20IX,\x20Xa,\x20XI,\x20XII\x20inaktive\x20ederek\x20fibronejen\x20fibrin\x20oluşumunu\x20önler.\x20Diğer\x20pıhtılaşma\x20faktörleri\x20üzerinden\x20de\x20etkiler.\x0a→\x20Venöz\x20tromboembolizm:\x2080\x20units/kg\x20IV\x20x\x201,\x20sonra\x2018\x20ünit/kg/saat\x20AKS\x20veya\x20Afib:\x2060\x20units/kg\x20IV\x20x\x201,\x20sonra\x2012\x20ünit/kg/saat\x0a⚠\x20Kanama\x20(etkilerini\x20geçirmek\x20için\x20protamin\x20verilebilir),\x20Dozlama\x20hatası.\x20Gebelik\x20ktg:C'},{'ad':'Hidrokortizon','bilgi':'✦\x20Akut\x20adrenal\x20yetmezlik,\x20Status\x20astmatikus,\x20vazopressör\x20refrakter\x20septik\x20şok\x0a-\x20Birden\x20çok\x20glukokortikoid\x20ve\x20minerelokortikoid\x20etkiler\x20mevcut.\x0a→\x20Akut\x20adrenal\x20yetmezlik,:\x20100mg\x20IV\x20bolus,\x20sonra\x2050\x20mg\x20IV\x206\x20saatte\x20bir.\x20Septik\x20şok:\x2050\x20mg\x20IV\x206\x20saatte\x20bir.\x20Status\x20astımatikus:\x201-2\x20mg/kg\x20IV\x206\x20saatte\x20bir.\x0a⚠\x20immünsüpresyon,\x20hiperglisemi.\x20Gebelik\x20ktg:C'},{'ad':'Hidromorfon','bilgi':'✦\x20Analjezi\x0a-\x20Analjezi\x20sağlayan\x20opoid\x20agonist\x20etki\x20ile\x20sedasyona\x20yardımcı.\x0a→\x201-2\x20mg\x20IV\x203-6\x20saatte\x20bir\x0a⚠\x20Solunum\x20depresyonu,\x20hipotansiyon.\x20Gebelik\x20ktg:C'},{'ad':'K-vit','bilgi':''},{'ad':a0_0x3f1f3c(0xe7,'iK%M'),'bilgi':a0_0x3f1f3c(0x11b,'^jWf')},{'ad':a0_0x3f1f3c(0x10f,'sPM&'),'bilgi':'','doz':'25mg\x20kapril\x20dil\x20altı'},{'ad':['keppra','Levetirasetam'],'bilgi':'KEPPRA\x20500\x20mg\x20/\x205\x20ml\x20konsantre\x20infüzyon\x20çözelti\x20içeren\x20flakon\x0aHer\x20bir\x20ml’\x20de\x20Levetirasetam\x20100\x20mg\x20','doz':'keppra\x201500mg\x20250cc\x20SF/1st'},{'ad':'Ketamin','bilgi':'✦\x20Aneljezi,\x20sedasyon,\x20RSI\x20indüksiyonunda\x0a-\x20Korteks\x20ve\x20limbik\x20sistem\x20üzerine\x20etki\x20eder,\x20NMDA\x20reseptör\x20antagonisti\x0a→\x20Subdissosiyatif:\x200.1-0.5\x20mg\x20/\x20kg\x20IV.\x20Prosedürel\x20sedasyon:\x200.5-1\x20mg\x20/\x20kg\x20IV.\x20RSI\x20indüksiyon:\x201-2\x20mg\x20/\x20kg\x20IV\x0a⚠\x20laringospazm,\x20(benzodiazepinler\x20ve\x20barbituratlarla\x20tedavi\x20edin),\x20hipertansiyon,\x20taşikardi.\x20(Kafa\x20içi\x20basınç\x20artışı\x20yaptığı\x20görüşü\x20son\x20çalışmalarla\x20artık\x20destek\x20görmemektedir.\x20Kafa\x20travmalı\x20hastalarda\x0ada\x20uygulanabileceği\x20son\x20derlemelerde\x20belirtilmektedir).\x0aGebelik\x20ktg:D'},{'ad':'krs.insülin','bilgi':'','doz':a0_0x3f1f3c(0x114,'*4pN')},{'ad':'Labetalol','bilgi':a0_0x3f1f3c(0xe4,'QLPB')},{'ad':'Lidokain','bilgi':a0_0x3f1f3c(0x120,'jG)e')},{'ad':'Lorazepam','bilgi':a0_0x3f1f3c(0xf8,'No3X')},{'ad':a0_0x3f1f3c(0xf5,'Oc6G'),'bilgi':a0_0x3f1f3c(0x109,'IyM3')},{'ad':a0_0x3f1f3c(0xeb,'IyM3'),'bilgi':'✦\x20Artmış\x20kafa\x20içi\x20basıncı,\x20herniasyona\x20gidiş\x0a-\x20osmotik\x20diüretik\x0a→\x201\x20gram/kg\x20IV\x0a⚠\x20dehidratasyona\x20neden\x20olabilir.'},{'ad':a0_0x3f1f3c(0xdf,'xNX$'),'bilgi':a0_0x3f1f3c(0xe9,'G0]r')},{'ad':'Metoheksital','bilgi':'✦\x20prosedural\x20sedasyon\x0a-\x20kortikal\x20ve\x20serebellar\x20sedayon\x20yapar,\x20hipnoz\x0a→\x201mg/kg\x20IV,\x20sonra\x200.5\x20mg/kg\x20her\x202-5\x20dakikada\x20bir\x0a⚠\x20laringospazm,\x20solunum\x20depresyonu,\x20hipotansiyon.\x20Gebelik\x20ktg:B'},{'ad':[a0_0x3f1f3c(0xfd,'o^4P'),'Metoklopramid'],'bilgi':a0_0x3f1f3c(0xda,'seh]'),'doz':'1amp\x20metpamid\x20100cc\x20SF\x20IV\x20inf'},{'ad':'Midazolam','bilgi':'✦\x20Nöbeti\x20durdurmak,\x20prosedural\x20sedasyon,\x20ventilatör\x20sedasyon,\x20RSI\x0a-\x20GABA\x20inhibe\x20edici\x20etkilerini\x20arttırmaktadır.\x0a→\x20RSI\x20indüksiyon:\x200.1\x20mg\x20/\x20kg\x20IV\x0aSürekli\x20infüzyon:\x201-10\x20mg\x20/\x20saat\x0aProsedürel\x20Sedasyon:\x200,02-0,04\x20mg\x20/\x20kg\x20IV\x0a⚠\x20solunum\x20depresyonu,\x20hipotansiyon.\x20Gebelik\x20ktg:D\x20'},{'ad':'Morfin\x20Sülfat','bilgi':a0_0x3f1f3c(0xe8,'8$&c')},{'ad':a0_0x3f1f3c(0x118,'seh]'),'bilgi':'2\x20mL\x27lik\x20ampul\x20formunda\x20olup\x204\x20mg\x20tiyokolşikosid\x20içerir','doz':'1amp\x20muscoril\x20IM'},{'ad':['NaHCO3',a0_0x3f1f3c(0xec,'RqbZ')],'bilgi':a0_0x3f1f3c(0xed,'an6C'),'doz':'10amp\x20NaHCO3\x20IV\x20puşe'},{'ad':'Nalokson','bilgi':'✦\x20Doğal\x20veya\x20sentetik\x20opiodlerin\x20etkilerini\x20geriye\x20döndürmek.\x0a-\x20Opiod\x20reseptörlerini\x20antagonize\x20eder.\x0a→\x200.4\x202\x20mg\x20IV/IM\x0a⚠\x20Allerji.\x20Gebelik\x20ktg:C'},{'ad':'Nitrogliserin','bilgi':'✦\x20KKY,\x20anjina,\x20HT\x0a-\x20venodilatatör,\x20cGMP\x20üretimini\x20stimüle\x20eder.\x0a→\x205-200mcg/dak,\x203-5dk\x20da\x20bir\x2010\x20mcg\x20etki\x20edene\x20kadar\x20arttırabilir.\x20Yüksek\x20dozlar\x20genellikle\x20pulmoner\x20ödemde\x20kullanılır.\x20Önerilen\x20başlama\x20dozu\x0a>5mcg/dak\x0a⚠\x20hipotansiyon,\x20methemoglebinemi.\x20Gebelik\x20ktg:C'},{'ad':'Nitroprusid','bilgi':'✦\x20Hipertansif\x20acil\x0a-\x20direkt\x20vazodilatatör,\x20NO\x20serbestler\x0a→\x200.3\x20mcg/kg/dak\x20IV\x20başlanır\x2010\x20mcg/kg/dak\x20kadar\x20titre\x20edilir.\x20Maksimum\x20dozdan\x2010\x20dakika\x20sonra\x20kan\x20basıncı\x20hala\x20kontrol\x20altına\x20alınamadıysa\x20nitroprusid\x20kesilir.\x0a⚠\x20siyanid\x20toksisitesi,\x20hipotansiyon,\x20methemoglobinemi.\x20Gebelik\x20ktg:C'},{'ad':'Norepinefrin','bilgi':a0_0x3f1f3c(0x10c,'(VQU')},{'ad':'Oktreotid','bilgi':'✦\x20Özefagus\x20varis\x20kanaması,\x20sülfünilüre\x20aşırı\x20dozu\x0a-\x20Damarları\x20vazokonstraksiyona\x20uğratır\x20(özellike\x20GI),\x20portal\x20damar\x20basıncını\x20düşürür.\x0a→\x20Özefagus\x20varis\x20kanaması:\x2050\x20mcg\x20IV\x20bolus,\x20sonra\x2050\x20mcg/saat\x20IV.\x20Sülfonilüre\x20tosisitesi:\x2050\x20mcg\x20SC\x206\x20saatte\x20bir\x0a⚠\x20Safra\x20kesesi\x20hastalıklarını\x20arttırır.\x20Gebelik\x20kategorsi\x20B'},{'ad':'Olanzapin','bilgi':a0_0x3f1f3c(0xf3,'66$U')},{'ad':'Pantoprazol','bilgi':a0_0x3f1f3c(0x113,'YI37')},{'ad':'pantpas','bilgi':'','doz':a0_0x3f1f3c(0xea,'iOTV')},{'ad':'parol','bilgi':'','doz':'1\x20flk\x20parol\x20IV\x2015dk\x20inf'},{'ad':'perlinganit','bilgi':'1\x20ampul\x20Perlinganitte®\x2010\x20mgr\x20gliserol\x20trinitrat\x20vardır.\x20İlacın\x20hazırlanışı\x20şu\x20şekildedir:\x20%\x200.9\x20NaCl\x20veya\x20%5\x20dekstroz\x20solusyonunda\x20çözülebilir.','doz':['1mp\x20perlinganit\x20100cc\x20SF:\x204cc\x20puşe,\x205cc/st\x20IV\x20inf']},{'ad':a0_0x3f1f3c(0xe3,'HOCn'),'bilgi':'✦\x20Analjezi\x0a-\x20kappa\x20opiat\x20reseptörü\x20agonisti\x0a→\x2025-100mg\x20IM\x20veya\x2025-50mg\x20IV\x0a⚠\x20Solunum\x20depresyonu.\x20Gebelik\x20ktg:C'},{'ad':['plavix',a0_0x3f1f3c(0x101,'^jWf')],'bilgi':'✦\x20AKS\x0a-\x20Trombosit\x20aktivasyonunu\x20engellemek\x20için\x20ADP\x20reseptörüne\x20irreversible\x20bağlanır.\x0a→\x2075-600\x20mg\x20PO\x0a⚠\x20Aktif\x20kanama,\x20alerjik\x20reaksiyonlar.\x20Gebelik\x20ktg:B.'},{'ad':a0_0x3f1f3c(0xfb,'@dlM'),'bilgi':'✦\x20antikolinesteraz\x20etkinliğe\x20sahip\x20olan\x20ajanlarla\x20zehirlenmelerde\x20(Organofosfat\x20intoksikasyonu).\x0a-\x20Kolinesterazı\x20yeniden\x20aktive\x20eder.\x0a→\x201-2\x20g\x20100\x20SF\x20içinde\x2015-30\x20dk\x0a⚠\x20Allerji.\x20Gebelik\x20ktg:C'},{'ad':'Prednizon','bilgi':a0_0x3f1f3c(0x117,'3zlB')},{'ad':'prednol','bilgi':'250mg\x20metilprednizolon\x20içerir','doz':'80mg\x20prednol\x20IV\x20puşe'},{'ad':'Propofol','bilgi':'✦\x20prosedürel\x20sedasyon,\x20ventilatör\x20sedasyon,\x20RSI\x0a-\x20GABAa\x20agonisti,\x20Na\x20kanal\x20blokörü\x0a→\x20Prosedürel\x20Sedasyon:\x201\x20mg/kg\x20IV\x20bolus\x20sonra\x0a0.5\x20mg/kg\x20\x203\x20dakika\x20bir\x0aRSI\x20indüksiyonun:\x201.5-2.5\x20mg/kg\x20IV\x0aVentilator\x20Sedasyon:\x205-50\x20mcg/kg/dak\x0a⚠\x20hipotansiyon,\x20anaflaksi,\x20Bradikardi,\x20apne.\x20Gebelik\x20ktg:B'},{'ad':a0_0x3f1f3c(0x110,'^jWf'),'bilgi':'✦\x20Heparinin\x20indüklediği\x20kanama\x0a-\x20Heparini\x20iyonik\x20bağlar\x0a→\x201mg\x20100ü\x20heparini\x20nötratilize\x20eder,\x205mg/dak\x20yapılması\x20önerilir.\x0a⚠\x20Daha\x20önceki\x20kullanımda\x20veya\x20balığa\x20karşı\x20allerjisi\x20olanlarda\x20anaflaksiye,\x20hızlı\x20infüzyonda\x20hipotansiyona\x20\x20sebep\x20\x20olabilir.\x20\x20Gebelik\x20\x20kategorisi\x20\x20C'},{'ad':'pulmicort','bilgi':'etken\x20maddesi\x20budesonid','doz':'1amp\x20pulmicort\x20inh'},{'ad':'Ranitidin','bilgi':a0_0x3f1f3c(0xff,'(VQU')},{'ad':'Regüler\x20İnsülin','bilgi':'✦\x20Hiperkalemi,\x20DKA/Hiperglisemik\x20hiperosmalar\x20koma,\x20Kalsiyum\x20kanal\x20bloker\x20toksikasyonu\x0a-\x20Periferik\x20glukoz\x20alımını\x20arttırır,\x20potasyumu\x20intraselüler\x20alana\x20çeker,\x0a→\x0aHiperkalemi:\x205-10\x20unit\x20IV\x20x\x201.\x20DKA’da\x200.05-0.1ü/kg/saat\x0ainfüzyon.\x0aKKB\x20toksikasyonu:\x20Eğer\x20kan\x20şekeri\x20<250\x20mg/dL\x20ise\x2025\x20gram\x20dekstroz\x20ile\x20birlikte\x201\x20unit/kg\x20bolus\x20verilir;\x20Kan\x20şekerini\x20100200\x20mg/dL\x20arasında\x20tutacak\x20şekilde\x200.1\x20-1\x20ü/kg/saatten\x20dekstroz\x20ile\x20titre\x20edilir.\x0a⚠\x20hipokalemi,\x20hipoglisemi,\x20sadece\x20IV\x20yoldan\x20verilebilir.\x20Gebelik\x20ktg:B'},{'ad':'Rokuronyum','bilgi':a0_0x3f1f3c(0x107,'v#*Z')},{'ad':'Süksinilkolin','bilgi':'✦\x20RSI\x20paralize\x0a-\x20depolarizan\x20nöromüsküler\x20ajan\x0a→\x201.5\x20mg/kg\x20(veya\x203-4\x20mg/kg\x20IM)\x0a⚠\x20hiperkalemi,\x20hiperkalemi\x20ile\x20birlikte\x20subakut\x20yanık/ezilme,\x20glokom,\x20kafa\x20içi\x20basıncını\x20artırır.\x20Gebelik\x20ktg:C'},{'ad':['teobag',a0_0x3f1f3c(0xf6,'@7Wf')],'bilgi':a0_0x3f1f3c(0x104,'kevu'),'doz':a0_0x3f1f3c(0xfc,'1vk%')},{'ad':'tetanoz','bilgi':'','doz':['tetanoz\x200',a0_0x3f1f3c(0x121,'J**D'),'1\x20doz\x20tetanoz\x20aşısı\x20IM']},{'ad':'Ticagrelor','bilgi':'✦\x20AKS\x20(unstabil\x20anjina,\x20STEMI,\x20NSTEMI)\x0a-\x20Trombosit\x20aktivasyonunu\x20engellemek\x20için\x20ADP\x20reseptörüne\x20reversible\x20bağlanır.\x0a→\x20180\x20mg\x20yükleme\x20dozu,\x20sonrasında\x20günde\x202*90mg\x0a⚠\x20Geçirilmiş\x20İntrakraniyal\x20hemeroji,\x20aktif\x20kanama,\x20şiddetli\x20karaciğer\x20yetmezliği.\x20Gebelik\x20ktg:C'},{'ad':'Tiyopental','bilgi':'✦\x20RSI\x0a-\x20GABA’nın\x20reseptörlerinden\x20ayrılma\x20hızını\x20yavaşlatır.\x0a→\x2050-75\x20MG\x20IV\x20yavaş\x20puşe\x0a⚠\x20Astım,\x20akut\x20intermitan\x20porfiri,\x20.Gebelik\x20ktg:C'},{'ad':'transamin','bilgi':a0_0x3f1f3c(0xde,'tfg('),'doz':'1gr\x20(4amp)\x20transamin\x20100cc\x20SF/10dk\x20IV\x20inf'},{'ad':['ventolin','salbutamol','Albuterol'],'bilgi':a0_0x3f1f3c(0xf7,'3zlB'),'doz':'1amp\x20ventolin\x20inh'},{'ad':'Verapamil','bilgi':a0_0x3f1f3c(0x11c,'f45&')},{'ad':['zofran','Ondansetron'],'bilgi':'✦\x20Bulantı\x20ve\x20kusma\x0a-\x20seratonin\x205-HT3\x20reseptörlerini\x20antagonize\x20eder,\x20\x20santral\x20etkili\x20antiemetik\x0a→\x204-8\x20mg\x20IV,\x204-6\x20saatte\x20bir,\x201amp\x204\x20mg\x0a⚠\x20torsad,\x20QT\x20uzaması,\x20Gebelik\x20ktg:B','doz':'1amp\x20zofran\x20IV\x20puşe'}];